Cancer drug development faces three persistent hurdles: tumors evolve resistance, clinical trials fail frequently due to poor patient selection, and many drugs are too toxic or difficult to deliver. Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) is tackling these issues simultaneously by integrating a novel DNA damage response (DDR) inhibitor with advanced nanoparticle delivery and artificial intelligence.
The company's lead candidate, ONC010, targets a DDR pathway distinct from PARP by inhibiting polynucleotide kinase 3'-phosphatase (PNKP). This enzyme plays a critical role in repairing DNA damage caused by radiation and chemotherapy. By blocking PNKP, ONC010 aims to prevent cancer cells from repairing therapy-induced damage, potentially overcoming resistance mechanisms that limit current treatments. The drug is paired with a proprietary nanoparticle delivery system designed to enhance tumor targeting and reduce systemic toxicity.
To improve clinical trial success rates, Onco-Innovations leverages its subsidiary Inka Health and the SynoGraph causal AI platform. These tools are intended to support patient stratification, identify biomarkers, and optimize trial design, addressing the high cost and failure rate of oncology trials. The company is currently advancing ONC010 through IND-enabling studies, manufacturing, and regulatory preparations.
This multi-pronged strategy reflects a broader industry shift toward combining novel biology, delivery technology, and AI. As precision oncology increasingly depends on biomarker-driven therapies and smarter trials, companies that integrate these frontiers may be better positioned to address persistent development challenges. For more information, visit the company's newsroom at ibn.fm/ONNVF.
InvestorWire, a communications platform specializing in press release syndication, distributed this release. The platform is part of the Dynamic Brand Portfolio at IBN, offering services such as article syndication to 5,000+ outlets and social media distribution. For details, see InvestorWire.com and its disclaimer at InvestorWire.com/Disclaimer.
